F-star Alpha Ltd.
Bispecific antibodies with modified “constant” regions
This article was originally published in Start Up
Executive Summary
F-star Alpha Ltd., a UK-based start-up recently spun out of F-star Biotechnology Ltd., believes its method of making bispecific antibodies can produce powerful therapeutics that are also easy to manufacture. While the parent company says the spin-out is essentially a commercial vehicle meant to leverage the value of the parent company's technology platform, F-star Alpha is dedicated to developing bispecific antibodies and antibody fragments as cancer treatments.
You may also be interested in...
Infectious Disease, Options Prevalent In 2014 Start-Up Dealmaking
The number of deals signed by biopharma start-ups increased 7% in 2014, which featured a bump in partnerships for infectious disease drugs and multiple option-to-acquire agreements.
Strategic Spin-Outs: Biotechs Structure Their Progeny For Success
Placing assets in new companies is a growing trend for biotech start-ups; freed to evolve differently, spin-outs are structured to increase exit options and maximize investor returns. We profile Envisia Therapeutics, F-star Alpha, Onkaido Therapeutics, Seragon Pharmaceuticals, and True North Therapeutics.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.